Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 5.23TCr 768.33Cr 673.9Cr 622.16Cr 574.93Cr 1.09TCr 74TCr 1.11TCr 7.48TCr 2.91TCr 36TCr 2.89TCr 2.82TCr 1,25000Cr P/E 2026 *
38.4x
P/E 2027 * 31.8x
Enterprise Value 4.72TCr 693.67Cr 608.42Cr 561.71Cr 519.07Cr 983.84Cr 66TCr 1TCr 6.75TCr 2.62TCr 33TCr 2.6TCr 2.55TCr 1,12800Cr EV / Sales 2026 *
5.86x
EV / Sales 2027 * 5.09x
Free-Float
61.14%
Yield 2026 *
0.99%
Yield 2027 * 1.19%
Manager TitleAgeSince
Chief Executive Officer 49 19/01/2022
Chief Executive Officer 70 07/10/1998
Director of Finance/CFO 45 07/08/2018
Director TitleAgeSince
Chairman 70 07/10/1998
Director/Board Member 49 18/07/2011
Director/Board Member 66 29/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 787.22Cr
-1.60%+2.02%+56.34%+168.30% 1,10200Cr
-1.44%+3.71%+69.07%+65.13% 64TCr
-0.75%+0.63%+33.13%+87.86% 45TCr
-1.35%+1.86%+29.96%+26.26% 34TCr
-0.71%+0.72%+28.85%+46.77% 29TCr
-1.31%-0.26%-28.18%-39.13% 22TCr
-0.03%+1.84%+23.90%+63.75% 20TCr
-0.40%+7.82%+22.29%+79.44% 17TCr
-0.08%+0.67%-6.17%-32.62% 14TCr
Average -0.70%+2.26%+25.47%+51.75% 39.39TCr
Weighted average by Cap. -1.04%+2.07%+39.83%+85.22%

Financials

2026 *2027 *
Net sales 805.08Cr 118.34Cr 103.79Cr 96Cr 89Cr 167.84Cr 11TCr 171.2Cr 1.15TCr 447.59Cr 5.54TCr 444.38Cr 434.64Cr 19TCr 955.7Cr 140.47Cr 123.21Cr 113.75Cr 105.12Cr 199.24Cr 13TCr 203.22Cr 1.37TCr 531.33Cr 6.58TCr 527.52Cr 515.96Cr 23TCr
Net income 140.64Cr 21Cr 18Cr 17Cr 15Cr 29Cr 1.98TCr 30Cr 201.23Cr 78Cr 968.63Cr 78Cr 76Cr 3.36TCr 171.51Cr 25Cr 22Cr 20Cr 19Cr 36Cr 2.41TCr 36Cr 245.4Cr 95Cr 1.18TCr 95Cr 93Cr 4.1TCr
Net Debt -507.91Cr -75Cr -65Cr -60Cr -56Cr -105.88Cr -7.15TCr -108Cr -726.74Cr -282.38Cr -3.5TCr -280.35Cr -274.21Cr -12TCr -440.53Cr -65Cr -57Cr -52Cr -48Cr -92Cr -6.2TCr -94Cr -630.33Cr -244.91Cr -3.03TCr -243.16Cr -237.83Cr -11TCr
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-